Effect of neoadjuvant chemotherapy combined with anthracycline and taxane in early or locally advanced breast cancer and its effects on ER,PR and Her-2
10.3969/j.issn.1005-1678.2017.03.059
- VernacularTitle:蒽环类与紫杉类联合新辅助化疗治疗早期或局部晚期乳腺癌的疗效及对患者ER、PR和Her-2的影响
- Author:
Feng LV
;
Xiaoe HUANG
;
Kebin LU
- Keywords:
early or locally advanced breast cancer;
anthracycline;
taxane;
neoadjuvant chemotherapy;
estrogen receptor;
progesterone receptor;
human epidermal growth factor receptor
- From:
Chinese Journal of Biochemical Pharmaceutics
2017;37(3):195-197
- CountryChina
- Language:Chinese
-
Abstract:
Objective To research the effect of neoadjuvant chemotherapy with anthracycline and taxane in early or locally advanced breast cancer and its effects on ER, PR and Her-2.Methods 120 cases of early or locally advanced breast cancer patients were selected as the research objects, according to the order of admission, the patients were divided into the observation group and the control group.The control group were given conventional chemotherapy with EC regimen (epirubicin +cyclophosphamide), while the observation group were treated with anthracyclines and taxanes.The clinical efficacy and the expression of ER, PR and Her-2 receptor in the two groups after treatment were compared.Results The total effective rate of the observation group was 73.33%, which was higher than that of the control group (53.33%) (P<0.05).After treatment, the positive expression level (0~+++) of ER receptor in the observation group were 20.00%, 15.00%, 35.00%, 30.00%, respectively, the positive expression level(0~+++) of PR receptor were 26.67%, 20.00%, 23.33% and 30.00%, respectively, were significantly better than those of the control group ( ER:31.67%, 21.67%, 28.33%, 18.33%, PR:40.00%, 25.00%, 20.00%, 15.00%) (P<0.05).But there was no significant difference between the two groups in the expression of Her-2 receptor (25.00%, 11.67%, 30.00%, 33.33% and 31.67%, 21.67%, 16.67%, 30.00%, respectively).The incidence of adverse reactions in the observation group and the control group were 6.67% and 21.67%, respectively, and there was significant difference between the two groups ( P<0.05 ) .Conclusion In the treatment of early or late stage breast cancer , anthracycline combined with taxane neoadjuvant chemotherapy has a significant effect, which can effectively improve the expression of ER and PR receptors.In addition to improve the effect of clinical treatment, and reduce the incidence of adverse reactions in a certain extent,so it can be used as a new adjuvant chemotherapy in the clinical application of the best option.
